https://www.selleckchem.com/pr....oducts/alflutinib-as
0001). Total radiation dose (419.3 ± 317.9 vs 998.3 ± 673 mGy, p less then 0.0001) and contrast administration (83.2 ± 22.3 mL vs 191.6 ± 33.4 mL, p less then 0.0001) were significantly lower in control group. There was no significant difference in 2-year success rate, 35.2% of patients had AF recurrence in the 3DRA group and 30.3% in the control group (p = 0.584). Major complications occurred in 2.9% and 1.5% of patients in 3DRA group and control group, respectively (p = 1.00. 3DRA is a feasible method of intra-pr
Like
Comment
Share
